Braveheart Bio (NASDAQ:BRVE) Rating Increased to Hold at Zacks Research

Zacks Research upgraded shares of Braveheart Bio (NASDAQ:BRVE) to a hold rating in a research note published on Tuesday,Zacks reports.

Several other equities research analysts have also weighed in on the company. Jefferies Financial Group assumed coverage on Braveheart Bio in a report on Monday. They issued a “buy” rating and a $48.00 price objective for the company. TD Cowen assumed coverage on shares of Braveheart Bio in a report on Monday. They set a “buy” rating on the stock. The Goldman Sachs Group started coverage on shares of Braveheart Bio in a research report on Monday. They set a “buy” rating and a $48.00 target price for the company. Cantor Fitzgerald initiated coverage on shares of Braveheart Bio in a research report on Monday. They issued an “overweight” rating and a $40.00 price target on the stock. Finally, Wall Street Zen upgraded shares of Braveheart Bio to a “hold” rating in a research note on Saturday, August 15th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $45.25.

Braveheart Bio Stock Up 2.5%

NASDAQ:BRVE opened at $26.95 on Tuesday. Braveheart Bio has a 1 year low of $24.31 and a 1 year high of $32.00.

Insider Buying and Selling

In related news, Director Erez Chimovits bought 1,940,000 shares of the business’s stock in a transaction on Friday, August 7th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $34,920,000.00. Following the purchase, the director directly owned 11,901,826 shares in the company, valued at $214,232,868. This trade represents a 19.47% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Orbimed Advisors Llc bought 1,940,000 shares of Braveheart Bio stock in a transaction on Friday, August 7th. The shares were bought at an average cost of $18.00 per share, with a total value of $34,920,000.00. Following the acquisition, the director directly owned 11,901,826 shares in the company, valued at approximately $214,232,868. This represents a 19.47% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought 8,751,942 shares of company stock valued at $157,534,956 in the last 90 days.

Braveheart Bio Company Profile

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.